Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 321.66M P/E - EPS this Y -7.10% Ern Qtrly Grth -
Income -43.03M Forward P/E -10.81 EPS next Y -10.00% 50D Avg Chg 45.00%
Sales 187.22M PEG - EPS past 5Y - 200D Avg Chg 127.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -6.00%
Recommedations 1.70 Quick Ratio 1.03 Shares Outstanding 209.60M 52W Low Chg 618.00%
Insider Own 1.91% ROA -8.43% Shares Float 190.40M Beta -
Inst Own 27.30% ROE - Shares Shorted/Prior 11.86M/13.40M Price 1.73
Gross Margin 83.27% Profit Margin -22.99% Avg. Volume 2,142,154 Target Price 5.00
Oper. Margin -45.63% Earnings Date May 9 Volume 2,121,982 Change -5.98%
About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics, Inc. News
05/14/24 Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
05/11/24 Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)
05/10/24 Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
05/10/24 Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
05/10/24 Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations
05/09/24 Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
05/09/24 Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
05/02/24 Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
05/01/24 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/28/24 When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
03/28/24 FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
03/28/24 Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
03/27/24 Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
03/26/24 Akebia Awaits FDA Word On Second Crack At Vadadustat
03/17/24 Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
03/16/24 Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
03/14/24 Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter
03/14/24 Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
03/14/24 Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
03/11/24 Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
AKBA Chatroom

User Image Magic_Money Posted - 1 hour ago

$AKBA I want bonuses tied to either BO, share price, or both. No bonus based on nothing anymore.

User Image King_JK Posted - 2 hours ago

$AKBA From my personal point of view, firstly, since the company’s second flagship drug has been certified by the US FDA, it is determined that it will move towards a multi-billion dollar revenue market... Well, why is it still blank in this important position? Second. Does Butler deliberately control acquisitions? Merge information? So that he can announce it after he successfully obtains 9.8 million additional stock rewards. Based on these two points, and the company's high sales profit in the market in the future... Now 1$... I think this is a great opportunity... Based on the above description... That's why I boldly invested more than 500,000 shares of stock Over here...! Well...does anyone else agree with me?

User Image Vladdavceo Posted - 2 hours ago

$AKBA Monday Madness 🔥🤑🔥🦎🔥🔜🔜🔜🔜🔜🔜🔜🔜🔜🔜

User Image buythehornz127 Posted - 4 hours ago

$AKBA I Carolyn Rucci was hired by Akebia in 2021 & servers as Senior VP, Legal & General Counsel. Nicole Hadas, Senior VP, Chief Legal Officer, Corp. Secretary is scheduled to depart company on June 14, 2024. Do we expect Ms. Rucci to serve as interim Chief Legal Officer or is someone who worked under Ms. Hadas to be elevated? II Ellen Snow & Akebia mutually agreed on March 15, 2024 that she would transition from her role as Senior VP, Chief Financial Officer, Treasurer … John Butler, President, Chief Executive Officer will act as primary financial officer from transition date (March 22, 2024). No LinkedIn replacement hire in 65 days. Note that Butler isn’t acting CEO. Bylaws probably prohibit & he doesn’t have financial experience to do so. (Is Snow’s departure related to Nasdaq delisting overhang? (“In course of preparing financial statements for qtr. ended June 2023, co. identified certain accounting errors … filed by the co. w/ SEC for fiscal years … 2022, 2021, 2020 …”).

User Image King_JK Posted - 6 hours ago

$AKBA The reason why meme stocks will soar... is that retail investors all over the world will buy or sell... with traffic... they will naturally soar... look at Akba...? kindness His online management...seems a bit unsatisfactory...! All I can say is: the public relations consulting team needs to work harder... Although this is a company that treats kidney diseases, it also needs to let ordinary people know that this company exists...?

User Image King_JK Posted - 6 hours ago

$AKBA Looking back at the expert target prices on this year's forum articles in 2020... Ever 10$? 15$?20$?30$? After 4 years, AKBA is still at a low ebb... Well Hopefully the next four years will see AKBA rise to $30..or be worth $30 per share if acquired

User Image ra11adw Posted - 6 hours ago

$AKBA A penny stock that has many issues and is at $0.4 cents, then a guy who posts a picture and the stock does 7000% percent e.g FFIE last 5 days. Also other stocks that went up 100%+ e.g GME. Yes different sectors, market caps, revenues, ATMs, managements, debt, cash. But to make the following point: Then you got AKBA, 2 years cash runway, approved drugs, Europe soon, worldwide multi billion market access 2025 and barely moving from $1s and doing negative percentages because of a vote or other nonsensical reasons. Makes you question life and what the markets are, luck or just pure nonsense. Make it make sense!

User Image King_JK Posted - 12 hours ago

$AKBA Waiting for launch in June~!

User Image ROCKET123 Posted - 20 hours ago

$AKBA @john_Ennis @King_JK well thanks buddy but that silly guy is expressing the passion of this company and any day any time now it will become reality…hmmm💎

User Image TiTb Posted - 20 hours ago

$AKBA A company who merged allready or was bought allready but didn't announce it yet is not, I repeat, is not by any chance presenting at an investor conference. Especially not an HCW one. I sure hope that it was merged or been bought but was you see is not what you get. If I am wrong (and hope I am) feel free to correct it.

User Image roomza Posted - 21 hours ago

$AKBA

User Image roomza Posted - 21 hours ago

$AKBA seems to me like whom ever is “running “ this shit show with this silly valuation, would let it trickle up a little. Just to make it seem less absurd. imho.

User Image SublimeAdam Posted - 22 hours ago

$AKBA Hope everyone has a nice weekend 😎. Added a little play cash to my account to up my share count no matter what price it's at premarket Monday. Still bullish and happy to accumulate.

User Image ra11adw Posted - 22 hours ago

$AKBA AKBA is so undervalued in many ways it’s actually insane, how it’s even around $1 is perplexing. Regardless of Butler management, dilution or delays. Even market sentiment or trust should not factor, this should not be $1, it should be $5-$10 minimum today with all the potential and approved drugs. There are companies out there with big debt, limited cash and not even profitable for years, or have FDA approved drugs yet are high $2.00-$10.00. AKBA has 2 year cash runway 42 million for operations, loans activated and more available and institutions loading up. They will literally release approved products like a new playstation portable to europe and a PS6 in 2025, all ready and packed or on a shelf ready to bring millions and billions revenues. Yet it’s only valued today at $1, thats just unbelievable.

User Image Maiquyen003 Posted - 23 hours ago

$AKBA

User Image ROCKET123 Posted - 1 day ago

$AKBA Sure does feel good sitting with Vafseo in the bag…hmmm💎

User Image ONLYPHARMS Posted - 1 day ago

$AKBA so nobody thinks by not filling these positions would point to a merger/buyout??

User Image PappyVan Posted - 1 day ago

$AKBA Feeling bullish for the upcoming week! Let’s go!!! 💚🍀 🦗

User Image PharmaExpert Posted - 1 day ago

$AKBA is it monday yet! 🔥 https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-2nd-annual-hcw-bioconnect-investor-conference-302144820.html

User Image robert801 Posted - 1 day ago

@slacktime @Steve_TheBull_Rogers @jacksparo slack jack hardly day trades not sure your theory of him buying in before everyone then selling once his followers buy in. @jacksparo has also posted his trades and support in $AKBA $ICU $KULR even being down. Sure he posts a lot more his winnings but who doesn't?

User Image buythehornz127 Posted - 1 day ago

$AKBA BUTLER’S PLAN II - Mystery. The departure of Ellen Snow, Chief Financial Officer was on ~March 15, 2024. The departure of Nicole Hadas, Chief Legal Officer is June 14, 2024. The departure of Michael Dahan, Chief Operating Officer is June 28, 2024. Executives numbered 2,3,4 are leaving Akebia at a time that it is on the cusp of launching a drug on multiple continents. Not a good look? John P. Butler, CEO is going to have three new and unknown top executives working with him at this critical time. Not a good look? Akebia has retained no executive search committee for any of the three executives? Not a good look? Akebia posted CFO position on LinkedIn ~63 days ago. No hire yet. Not a good look? Akebia has said nothing about whether Snow, Hadas, Dahan may be replaced from within. Not a good look? DO NOT THINK FOR ONE MOMENT THAT AKEBIA CAN SAIL ITS SHIP IN OPEN WATERS WITHOUT THESE EXECUTIVES. FIRST TIME THERE IS A FINANCIAL, LEGAL, OPERATIONS MISTAKE WE ARE SUED. NOT A GOOD LOOK.

User Image georgeyann Posted - 1 day ago

$AKBA I was assigned 8k shares!

User Image feroga62 Posted - 1 day ago

$AKBA after hour 37596200 shares!!??, is it weird

User Image buythehornz127 Posted - 1 day ago

$AKBA BUTLER’S PLAN: (1)Decouple NDD from DD in NDA; (2)Secure $55M exit payment from Otsuka, double economics; (3)Slash costs/expenses by 42%; (4)Provide better benefit-risk analysis to FDA; (5)Push Vadadustat Covid-19/ARDS to “near miss;” (6)File FDRR w/ FDA;(7)Give FDA additional clarifying information;(8)Allow competitors to implode; (9)Attend Type A meeting; (10)Produce Japanese data/FO2CUS study to FDA; (11)Secure drug approval in Japan, South Korea, Europe, UK, Australia, Taiwan, USA; (12)Maintain partnerships w/ Mitsubishi Tanabe, Vifor Pharma, Aveora, Medice; (13)Rework loan principal payments/maturity date w/ BlackRock; (14)Cash for operations for 2+ years; (15)Engage w/ FDA on labeling, dosing, subset population w/ positive benefit risk-analysis; (16)File for CMS’ TDAPA designation; (17)Prepare for drug launches on multiple continents; (18)Progress pipeline - Vadadustat NDD/Covid-19/ARDS, AKB 9090 ARDS, AKI, AKB 10108 ROP, BPD; (19)Sell Auryxia USA/Europe; (20)Report revenue

User Image gaboriar Posted - 1 day ago

$AKBA also made a few bucks on long putting gme. I could have made a killing but you can’t intelligently plan around lunacy. Took my profits. Also short puts on asts paid.

User Image gaboriar Posted - 1 day ago

$AKBA I was assigned my puts early. Rewrote them. Also sold 15k yesterday and grabbed short ALT puts that expired same day. Got assigned too. Will sell short calls on ALT Monday deep ITM so I get called . Then will buyback Akba by selling more short puts. Just because Butler isn’t doing shit doesn’t mean I won’t.

User Image mauriz Posted - 1 day ago

$AKBA the sun Is 🩴shining🚣 Have a niiice weekend

User Image PappyVan Posted - 1 day ago

$AKBA Butler has a plan. If you don’t trust Butler, please sell and move on. If you know what you own, well then you’re going to do well.

User Image Rio307 Posted - 1 day ago

$AKBA Cheers my friends. I hope next week is better than this one. Take some time to enjoy family and friends this weekend. I truly appreciate this team 🍻

User Image ZanklinFrappa Posted - 1 day ago

$AKBA have a good weekend, Akebians Stay strong, stay holding and Remain

Analyst Ratings
HC Wainwright & Co. Buy Mar 28, 24
HC Wainwright & Co. Buy Mar 15, 24
HC Wainwright & Co. Buy Nov 17, 23
HC Wainwright & Co. Buy Sep 27, 23
HC Wainwright & Co. Buy Aug 28, 23
HC Wainwright & Co. Neutral Aug 11, 23
HC Wainwright & Co. Neutral Jun 21, 23
HC Wainwright & Co. Neutral Jun 14, 23
HC Wainwright & Co. Neutral Jun 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hadas Nicole R. SVP, Chief Legal Off.. SVP, Chief Legal Officer May 24 Sell 1.22 63,186 77,087 524,344 05/25/23
Dahan Michel SVP, Chief Operating.. SVP, Chief Operating Officer May 24 Sell 1.22 95,478 116,483 574,037 05/25/23
Butler John P. CEO and President CEO and President Feb 28 Sell 2.17 79,026 171,486 1,403,247 03/02/22
Burke Steven Keith SVP, Chief Medical O.. SVP, Chief Medical Officer Feb 28 Sell 2.17 15,056 32,672 217,663 03/02/22
Cotreau Violetta SVP, Chief Accountin.. SVP, Chief Accounting Officer Feb 28 Sell 2.15 3,946 8,484 29,121 03/02/22
Dahan Michel SVP, Chief Operating.. SVP, Chief Operating Officer Feb 28 Sell 2.17 21,533 46,727 297,017 03/02/22
Faulkingham Dell SVP, CCO SVP, CCO Feb 28 Sell 2.17 13,184 28,609 173,841 03/02/22
Hadas Nicole R. SVP, Chief Legal Off.. SVP, Chief Legal Officer Feb 28 Sell 2.17 21,062 45,705 304,241 03/02/22
Spellman David A SVP, CFO and Treasur.. SVP, CFO and Treasurer Feb 28 Sell 2.16 8,203 17,718 128,599 03/02/22
Faulkingham Dell CCO CCO Mar 02 Sell 3.4 6,749 22,947 128,825 03/02/21
Hadas Nicole R. SVP, Chief Legal Off.. SVP, Chief Legal Officer Mar 02 Sell 3.4 14,285 48,569 263,171 03/02/21